[11c]az14132516
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 27, 2023 (NCT05818514)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- C-C chemokine receptor type 9Radiopharmaceutical
CCR9 radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 11-carbon
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06432764 | Phase 1 | Aug 30, 2024 | AstraZeneca, Karolinska Institute |
| NCT06053424 | Phase 1 | Sep 25, 2023 | AstraZeneca, Karolinska Institute |
| NCT05818514 | Early Phase 1 (Phase 1) | Apr 27, 2023 | AstraZeneca, Karolinska Institute |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 1 | 2023 |
| Karolinska Institute | Academic/Hospital | 3 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1